Skip to Content
Merck
CN

Key Documents

View All Documentation

P8828

Pergolide mesylate salt

≥98%, solid

Synonym(s):

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C19H26N2S · CH4O3S
CAS Number:
66104-23-2
Molecular Weight:
410.59
NACRES:
NA.77
PubChem Substance ID:
24277927
UNSPSC Code:
12352200
MDL number:
MFCD00153859
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥98%

form

solid

optical activity

[α]20/D −35°, c = 0.2 in pyridine(lit.)

color

white

solubility

ethanol: 2 mg/mL, DMSO: 5.2 mg/mL, H2O: insoluble

originator

Valeant

storage temp.

−20°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1

InChI key

UWCVGPLTGZWHGS-ZORIOUSZSA-N

Gene Information

human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816)

Biochem/physiol Actions

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

Features and Benefits

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H300

Hazard Classifications

Acute Tox. 2 Oral

Storage Class

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLBM6092V
SLBF6838V
070M2011V
070M2011
119K1638

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P Barone et al.
Neurology, 53(3), 573-579 (1999-08-17)
To determine whether pergolide monotherapy provides symptomatic relief in early PD. Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 dopamine agonist, has been studied as
Richard P Allen et al.
Sleep medicine, 12(5), 431-439 (2011-04-16)
Assess the rate of augmentation as it occurs during standard long-term dopaminergic treatment of RLS, potential risk factors or predictors of augmentation, the relationship between treatment duration and augmentation, and the clinical impact of augmentation on subjects' health outcomes. Two
Hanna Scholz et al.
The Cochrane database of systematic reviews, (3)(3), CD006009-CD006009 (2011-03-18)
According to clinical guidelines, dopamine agonists are the first-line treatment of restless legs syndrome (RLS). To evaluate efficacy and safety of dopamine agonists for RLS. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 4)
View All Related Papers